Mind Medicine (MindMed) Inc. (MNMD)

Market Cap	945.77M
Revenue (ttm)	n/a
Net Income (ttm)	-114.52M
Shares Out	76.09M
EPS (ttm)	-1.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,241,302
Open	12.52
Previous Close	12.64
Day's Range	11.88 - 12.63
52-Week Range	4.70 - 14.30
Beta	3.31
Analysts	Strong Buy
Price Target	26.71 (+114.88%)
Earnings Date	Oct 31, 2025

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: MNMD
• Website: https://www.mindmed.co

Analyst Summary

According to 7 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price target is $26.71, which is an increase of 114.88% from the latest price.

Price Target

$26.71

(114.88% upside)

Analyst Consensus: Strong Buy